Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

181.21 -1.73 (-0.95%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript ↗

February 20, 2024

AXSM earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones ↗

February 20, 2024

Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.

Via Benzinga

Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug ↗

February 20, 2024

The company is testing a treatment for patients with agitation due to Alzheimer's disease.

Via Investor's Business Daily

Earnings Outlook For Axsome Therapeutics ↗

February 19, 2024

Via Benzinga

2 Stocks That Could Double Your Money in 5 Years ↗

February 08, 2024

These market-beating stocks could be just getting started.

Via The Motley Fool

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗

February 06, 2024

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.

Via Benzinga

The Latest Analyst Ratings For Axsome Therapeutics ↗

February 06, 2024

Via Benzinga

The Analyst Landscape: 6 Takes On Axsome Therapeutics ↗

January 16, 2024

Via Benzinga

Analyst Expectations for Axsome Therapeutics's Future ↗

November 07, 2023

Via Benzinga

Earnings Scheduled For February 20, 2024 ↗

February 20, 2024

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.

Via Benzinga

Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own' ↗

January 26, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK).

Via Benzinga

Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says ↗

January 25, 2024

Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.

Via Benzinga

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗

January 23, 2024

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years ↗

January 03, 2024

Is it too late to invest in these fast-growing stocks?

Via The Motley Fool

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

January 02, 2024

The types of innovative drugs these companies develop are always in high demand.

Via The Motley Fool

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Analyst Ratings for Axsome Therapeutics ↗

September 25, 2023

Via Benzinga

Prediction: These 3 Stocks Will Soar in 2024 ↗

January 01, 2024

Investors could enjoy an especially happy new year with these great stocks.

Via The Motley Fool

3 Unstoppable Stocks to Buy Right Now ↗

December 10, 2023

These stocks could be just the ticket for investors seeking strong growth.

Via The Motley Fool

3 Biotech Stocks That Could Be Millionaire Makers ↗

November 22, 2023

Many biotech stocks offer exciting long-term growth prospects.

Via The Motley Fool

3 Growth Stocks to Buy Right Now Without Any Hesitation ↗

November 11, 2023

Investors shouldn't have to deliberate for too long about these great stocks.

Via The Motley Fool

3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates ↗

November 09, 2023

Can these promising growth stocks continue rising in value?

Via The Motley Fool

Topics Economy

Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth ↗

November 06, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m

Via Benzinga

Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript ↗

November 06, 2023

AXSM earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Riding the Wave: 3 Stocks That Can 10X by 2025 ↗

October 30, 2023

Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025.

Via InvestorPlace

Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now ↗

October 27, 2023

Now, you can scoop up these future growth winners for a bargain.

Via The Motley Fool

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

October 25, 2023

Neither has performed well on the stock market this year.

Via The Motley Fool

3 No-Brainer Stocks to Buy Right Now for Less than $100 ↗

October 23, 2023

You can start with a small investment and win big over time.

Via The Motley Fool

2 Top Biotech Stocks to Buy in October ↗

October 03, 2023

Growth catalysts lie ahead for both of these players.

Via The Motley Fool

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating ↗

September 27, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

Headline News about Axsome Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today